Eisai Inc., the US subsidiary of Japan’s Eisai Co. Ltd., and Purdue Pharma LP have joined forces to develop and commercialize Eisai’s lemborexant. The initial indication for the dual orexin receptor antagonist candidate is insomnia and the two companies will share the costs of the drug's global clinical studies in this area.
However, they may also seek to develop other indications in the future.